1. Scrip
  2. >>Business

The BioPharma Shares Rising On Omicron Hopes And Fears

Room For New Options In Vaccines And Antibodies

 
• By Andrew McConaghie

Adagio Therapeutics and Gritstone bio are two companies who could add to the armamentarium against Omicron.

London Waterloo train station
Waterloo station, London, UK: confirmed cases of the new variant have led the government to reimpose mandatory mask wearing on public transport. • Source: Alamy

Concerns about the danger posed by the Omicron SARS-CoV2 variant have gripped the world in the last week, even while public health scientists and biopharma researchers race to establish if, as feared, it proves to be more transmissible than previous variants and potentially evade existing vaccines.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Zelluna Believes Its TCR Tech Can Unlock Natural Killer Cell Potential

 
• By Andrew McConaghie

While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.